XGN
Exagen Inc.
XGN
Exagen Inc.
Exagen delivered a standout quarter, with 16% revenue growth, record ASP, and near-breakeven adjusted EBITDA, reinforcing the turnaround thesis. XGN raised full-year revenue guidance to $72-75M, with
Exagen earns a Buy rating as revenue growth accelerates, ASPs improve, and break-even appears within reach despite ongoing cash burn. XGN leverages a growing proprietary autoimmune diagnostics databas